Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Titanji, Boghuma K; Farley, Monica M.; Mehta, Ashish; Connor-Schuler, Randi; Moanna, Abeer; Cribbs, Sushma K.; O’Shea, Jesse; DeSilva, Kathryn; Chan, Bonnie; Edwards, Alex; Gavegnano, Christina; Schinazi, Raymond F.; Marconi, Vincent C.

doi:10.1093/cid/ciaa879

Cited by 124 publications

(131 citation statements)

References 12 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Twelve of the 15 patients recovered, and vitals and inflammatory markers were seen to improve after baricitinib was initiated. Two patients however developed serious bacterial or fungal infections due to prolonged ICU stay ( 157 ). A phase III double blind placebo-controlled randomized trial involving baricitinib (NCT04421027) is currently ongoing to assess the efficacy and safety of the drug as a potential immune inhibitor preventing cytokine storm and viral entry.…”

Section: Treatment Protocolsmentioning

confidence: 99%

SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment

et al. 2020

View full text Add to dashboard Cite

The emergence and rapid spread of SARS-CoV-2 in December 2019 has brought the world to a standstill. While less pathogenic than the 2002–2003 SARS-CoV, this novel betacoronavirus presents a global threat due to its high transmission rate, ability to invade multiple tissues, and ability to trigger immunological hyperactivation. The identification of the animal reservoir and intermediate host were important steps toward slowing the spread of disease, and its genetic similarity to SARS-CoV has helped to determine pathogenesis and direct treatment strategies. The exponential increase in cases has necessitated fast and reliable testing procedures. Although RT-PCR remains the gold standard, it is a time-consuming procedure, paving the way for newer techniques such as serologic tests and enzyme immunoassays. Various clinical trials using broad antiviral agents in addition to novel medications have produced controversial results; however, the advancement of immunotherapy, particularly monoclonal antibodies and immune modulators is showing great promise in clinical trials. Non-orthodox medications such as anti-malarials have been tested in multiple institutions but definitive conclusions are yet to be made. Adjuvant therapies have also proven to be effective in decreasing mortality in the disease course. While no formal guidelines have been established, the multitude of ongoing clinical trials as a result of unprecedented access to research data brings us closer to halting the SARS-CoV-2 pandemic.

show abstract

Section: Treatment Protocolsmentioning

confidence: 99%

SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nevertheless, no significant relationship was observed between treatment with these two drugs and clinical improvement. 94 According to some reports, baricitinib may lead to anemia, and even, in severe cases, may associate with leukopenia, lymphocytopenia, and thrombocytopenia. Accordingly, a review showed that treatment with baricitinib could lead to anemia in patients with severe COVID-19.…”

Section: Baricitinibmentioning

confidence: 99%

<p>Current Options in the Treatment of COVID-19: A Review</p>

Teimury¹,

Khaledi²

2020

RMHP

View full text Add to dashboard Cite

Novel Coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in China and spread rapidly all around the world infecting many people. To date, no specific vaccines and drugs have been developed for this disease. Also, due to the COVID-19 pandemic and high prevalence of the infected patients, the drugs and the therapies of other past viral epidemics have been used for this disease. Many studies have been performed on the specific treatments to find whether or not they are effective on COVID-19 patients. In this review, we collected information about the most widely used drugs to treat COVID-19 (coronavirus disease 2019) belonging to groups of antivirals, antibiotics, immune modulators, and anticoagulants. Some of these compounds and drugs were used directly by inpatients, so researchers have examined others in laboratory conditions. This study considered the pros and cons of using these treatments separately and together and compared their results. By studying this review, we hope to provide useful information for researchers.

show abstract

“…In one of the recent pilot study, 12 moderately SARS-CoV-2 infected patients were found to show improvements in clinical and laboratory parameters with baritinicib ( Cantini et al., 2020 ). In another non-controlled, retrospective cohort study with 15 moderate to severe COVID-19 patients, it was reported that baritinicib with HCQ leads to recovery and clinical improvements ( Titanji et al., 2020 ). However, the efficacy of baritinicib could not be confirmed with scant and insufficient clinical results until enough data about the clinical efficiency and safety profile of baricitinib (NCT04321993, NCT04320277) is available.…”

Section: Adjunctive/supportive Care Against Covid-19mentioning

confidence: 99%

Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines

et al. 2020

View full text Add to dashboard Cite

The recent outbreak of the COVID-2019 (coronavirus disease 2019) due to the infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has realized the requirement of alternative therapeutics to mitigate and alleviate this lethal infection. These alternative therapies are effective when they are started at the initial stage of the infection. Some drugs that were used in previous other related infections SARS-CoV-2003 and Middle East respiratory syndrome coronavirus (MERS-CoV)-2012 could be potentially active against currently emerging SARS-CoV-2. This fact imparts some rationale of current interventions, in the absence of any specific therapeutics for SARS-CoV-2. It is imperative to focus on the available antimicrobial and adjunct therapies during the current emergency state and overcome the challenges associated with the absence of robust controlled studies. There is no established set of drugs to manage SARS-CoV-2 infected patients. However, closely following patients’ conditions and responding with the dosage guidelines of available drugs may significantly impact our ability to slow down the infection. Of note, it depends upon the condition of the patients and associated comorbid; therefore, the health workers need to choose the drug combinations judiciously until COVID-19 specific drug or vaccine is developed with the collective scientific rigor. In this article, we reviewed the available antimicrobial drug, supportive therapies, and probable high importance vaccines for the COVID-19 treatment.

show abstract

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Cited by 124 publications

References 12 publications

SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment

SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment

<p>Current Options in the Treatment of COVID-19: A Review</p>

Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines

Contact Info

Product

Resources

About